Search This Blog

Friday, May 29, 2026

Agios to discontinue tebapivat development in lower-risk myelodysplastic syndromes as Phase 2b misses

 

Agios to discontinue tebapivat development in lower-risk myelodysplastic syndromes after Phase 2b trial misses efficacy threshold

  • Phase 2b study failed its predefined efficacy threshold but identified no new safety issues for tebapivat.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)